Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bosnia | Brazil | Croatia | India | Ireland | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other
Phase 2: Mesothelioma|Acute Myeloid Leukemia|Pleural Cancer|Non-Small-Cell Lung Cancer|Peripheral Nervous System Diseases|Alzheimer Disease|Carcinoma, Merkel Cell|Hereditary Sensory and Autonomic Neuropathies|Acute Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Pancreatic Cancer|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Blast Crisis|Preleukemia|Adenocarcinoma|Amyotrophic Lateral Sclerosis|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Myeloid, Accelerated Leukemia
Phase 1: Adenocarcinoma|Uterine Cancer|Pancreatic Ductal Carcinoma|Sarcoma|Colorectal Cancer|Cervical Cancer|Melanoma|Pancreatic Cancer|Kidney Cancer|Renal Cell Carcinoma|Graft vs Host Disease|Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified|Stem Cell Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RR-DVIVO | P3 |
Unknown Status |
Unknown |
2027-12-31 |
|
| NCI-2024-08121 | P1 |
Not yet recruiting |
Uterine Cancer|Adenocarcinoma|Pancreatic Cancer|Cervical Cancer|Kidney Cancer|Renal Cell Carcinoma|Melanoma|Colorectal Cancer|Pancreatic Ductal Carcinoma |
2027-10-30 |
|
| ChiCTR2400089707 | N/A |
Not yet recruiting |
Kidney Diseases |
2026-01-01 |
|
| SENSE | P2 |
Recruiting |
Hereditary Sensory and Autonomic Neuropathies |
2025-08-01 |